Lucite commemorative, incorporating a drug vial, celebrating the first product shipment by generic pharmaceutical company Civica.
(9AKL475)
The Corporate Presence can provide a range of commemorative designs, including those for FDA approvals, treatment studies, licensing, development, and commercialization agreements, and drug launches. We have unmatched expertise and experience in embedding drug vials.
Lucite commemorative, incorporating a drug vial, celebrating the first product shipment by generic pharmaceutical company Civica.
(9AKL475)Custom Lucite with an embedded drug vial commemorating FDA approval of ELAHERE. Developed by ImmunoGen, the drug was granted accelerated FDA approval as a treatment for ovarian cancer. (23AKL266)
Custom Lucite, with an embedded drug vial, celebrating FDA approval of Cosela. (20ADH005)
Crystal commemorative recognizing team members in a first in-human clinical study of an anti-tumor therapy.
(9AJH024)Custom crystal celebrating the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA). The application, related to Impel NeuroPharma’s migraine treatment INP104, was supported by a Phase 3, open-label STOP-301 Trial.
(20ALJ356)Crystal commemorative marking a licensing and commercialization agreement between Corbus Pharmaceuticals and CSPC Pharmaceutical Group. The agreement centers on a potential treatment for tumors associated with lung, breast, and prostate cancers. (23AZH089)
Custom crystal commemorative celebrating the launch of Wynzora Cream, a topical treatment for plaque psoriasis that received approval from the FDA (Food and Drug Administration) in 2020. The product launch resulted from a collaboration agreement between Denmark-based MC2 Therapeutics, and EPI Health, a specialty pharmaceutical firm headquartered in Charleston, South Carolina.
(21ADH022)Custom crystal commemorative, incorporating a periodic table theme, marking a licensing and commercialization agreement for a cancer drug developed by Rockville, Maryland-based biotech firm GlycoMimetics. The agreement applies to mainland China, Hong Kong, Taiwan, and Macau.
(20ALJ071)Lucite commemorative marking the first patient dosed in a clinical study involving LunAIRo. Developed by Apnimed, the drug is intended for the treatment of obstructive sleep apnea. (23AZH173)
